NASDAQ:PHAR Pharming Group Q3 2025 Earnings Report $14.32 -0.23 (-1.55%) Closing price 03:58 PM EasternExtended Trading$14.24 -0.08 (-0.56%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Pharming Group EPS ResultsActual EPSN/AConsensus EPS $0.05Beat/MissN/AOne Year Ago EPSN/APharming Group Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APharming Group Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time1:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Pharming Group Earnings HeadlinesPharming Group (ENXTAM:PHARM): Assessing Valuation Following Major Cost-Cutting and Restructuring MoveOctober 10, 2025 | finance.yahoo.comPharming Group Announces Restructuring to Cut Costs and Boost GrowthOctober 8, 2025 | msn.comMissed the Last 10,000% Surge? Here’s Your Next ChanceWall Street’s already moving while most traders are still reacting — powered by data and AI tools the rest of us don’t see. That’s why we built Fierce Free Alerts: real-time signal notifications that cut through the noise and trigger the moment smart setups start forming.October 15 at 2:00 AM | Fierce Investor (Ad)Pharming announces 20% net reduction in non-commercial, non-medical headcountOctober 7, 2025 | msn.comPharming Group provides update on previously announced G&A expense reduction planOctober 6, 2025 | markets.businessinsider.comPharming Group (NASDAQ:PHAR) versus Immix Biopharma (NASDAQ:IMMX) Critical ComparisonOctober 5, 2025 | americanbankingnews.comSee More Pharming Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pharming Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharming Group and other key companies, straight to your email. Email Address About Pharming GroupPharming Group (NASDAQ:PHAR) N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins. The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe. RUCONEST represents the first recombinant C1 inhibitor therapy, offering an alternative to plasma-derived treatments and addressing key safety and supply concerns associated with conventional sources. Pharming continues to support RUCONEST through lifecycle management initiatives and expanded patient access programs. Beyond its marketed product, Pharming’s research and development pipeline includes additional indications for C1 esterase inhibitor in prophylactic HAE treatment and novel programs targeting other rare and genetic disorders. Preclinical efforts leverage the same transgenic expression platform to explore therapies for conditions such as alpha-1 antitrypsin deficiency and metabolic disorders. Strategic collaborations and licensing agreements underpin the company’s approach to expanding its portfolio and reaching underserved patient populations. Pharming Group serves patients and partners across Europe, North America, Latin America and Asia-Pacific through a combination of direct commercial operations and regional partnerships. The company is led by Chief Executive Officer Sijmen de Vries, whose experience in biotechnology and global product commercialization supports Pharming’s mission to deliver life-transforming therapies to individuals affected by rare diseases.View Pharming Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff Concerns Upcoming Earnings CSX (10/16/2025)Interactive Brokers Group (10/16/2025)Bank of New York Mellon (10/16/2025)American Noble Gas (10/16/2025)Marsh & McLennan Companies (10/16/2025)Charles Schwab (10/16/2025)Travelers Companies (10/16/2025)Taiwan Semiconductor Manufacturing (10/16/2025)U.S. Bancorp (10/16/2025)American Express (10/17/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
